en · de · es · fr · pt
cardarine-notes.peptides6908.com › Info › Mechanism And Safety Research — Field Notes

Mechanism And Safety Research — Field Notes

By Editorial Desk · published 2026-05-09 · last reviewed 2026-06-24 · Info

If you have been reading about GW501516 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-06-24. Where a claim depends on a specific study, the study is described rather than over-claimed.

Mechanism and Safety Research

Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.

Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.

Identity and Pharmacological Mechanism

The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.

Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.

Cardarine at a glance

PropertyValueNotes
Primary targetPPARδNuclear receptor; not androgen receptor
Studied indicationsDyslipidemia; obesity; diabetesEarly clinical research; development discontinued
Rodent toxicityTumor formation in multiple tissuesDose-dependent findings in some studies
Human approvalNoneNo approved therapeutic use
Typical analytical methodLC-MS/MSUsed for identity and quantification

Mechanism and Research Context

In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.

GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.

Related pages on this site

Cardarine Identity and Mechanism

At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.

Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.

Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.

Detection and Regulatory Landscape

Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.

Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.

Supporting material

The resulting campaign was costly for both sides, but ultimately ended in disaster for France and the near-destruction of Napoleon's Grande Armée. French forces retreated from Russia by December 1812 and began reconstituting their lost strength. Encouraged by the defeat, Austria, Prussia, and several minor powers joined Russia, Britain, and Spain in a Sixth Coalition and began a campaign against France. The Sixth Coalition defeated Napoleon at Leipzig in October 1813. The allies then invaded France on two fronts: the Russians, Austrians, and Prussians invaded France from the east, while the British, Spanish, and Portuguese invaded France from the west. Coalition troops captured Paris in March 1814, forced Napoleon to abdicate in April, exiled him to the island of Elba, and restored power to the Bourbons. Napoleon escaped exile in February 1815 and reassumed control of France for around one hundred days, igniting the eponymous conflict. The allies formed the Seventh Coalition, which defeated him at Waterloo in June 1815 and exiled him to Saint Helena, where he died in 1821. The wars had profound consequences on history. New methods of warfare were introduced, including mass conscription and guerrilla warfare. Politically, the wars greatly influenced Europe through the advancements in civil law brought about by the Napoleonic Code, which was largely retained where it was adopted, and the spread of nationalism and liberalism. Independence movements emerged in Spanish America as a direct consequence of the wars, leading to the decline of the Spanish and Portuguese Empires.

Sodium is found in many different minerals, of which the most common is ordinary salt (sodium chloride), which occurs in vast quantities dissolved in seawater. Other solid deposits include halite, amphibole, cryolite, nitratine, and zeolite. Many of these solid deposits occur as a result of ancient seas evaporating, which still occurs now in places such as Utah's Great Salt Lake and the Dead Sea. Despite their near-equal abundance in Earth's crust, sodium is far more common than potassium in the ocean, both because potassium's larger size makes its salts less soluble, and because potassium is bound by silicates in soil and what potassium leaches is absorbed far more readily by plant life than sodium. Despite its chemical similarity, lithium typically does not occur together with sodium or potassium due to its smaller size. Due to its relatively low reactivity, it can be found in seawater in large amounts; it is estimated that lithium concentration in seawater is approximately 0.14 to 0.25 parts per million (ppm) or 25 micromolar. Its diagonal relationship with magnesium often allows it to replace magnesium in ferromagnesium minerals, where its crustal concentration is about 18 ppm, comparable to that of gallium and niobium. Commercially, the most important lithium mineral is spodumene, which occurs in large deposits worldwide. Rubidium is approximately as abundant as zinc and more abundant than copper. It occurs naturally in the minerals leucite, pollucite, carnallite, zinnwaldite, and lepidolite, although none of these contain only rubidium and no other alkali metals.

== History == The precise origin of absinthe is unclear. The medical use of wormwood dates back to ancient Egypt and is mentioned in the Ebers Papyrus from around 1550 BC. Wormwood extracts and wine-soaked wormwood leaves were used as remedies by the ancient Greeks. Moreover, some evidence exists of a wormwood-flavoured wine in ancient Greece called absinthites oinos. Lucretius' De Rerum Natura (I, 936–950) says that a drink containing wormwood was given as medicine to children in a cup with honey on the brim to make it drinkable. The first evidence of absinthe, in the sense of a distilled spirit containing green anise and fennel, dates to the 18th century. According to popular legend, it began as an all-purpose patent remedy created by Dr. Pierre Ordinaire, a French doctor living in Couvet, Switzerland, around 1792 (the exact date varies by account). Ordinaire's recipe was passed on to the Henriod sisters of Couvet, who sold it as a medicinal elixir. By other accounts, the Henriod sisters may have been making the elixir before Ordinaire's arrival. In either case, a certain Major Dubied acquired the formula from the sisters in 1797 and opened the first absinthe distillery named Dubied Père et Fils in Couvet with his son Marcellin and son-in-law Henry-Louis Pernod. In 1805, they built a second distillery in Pontarlier, France, under the company name Maison Pernod Fils. Pernod Fils remained one of the most popular brands of absinthe until the drink was banned in France in 1914.

== Taxonomic range == Venom is widely distributed taxonomically, being found in both invertebrates and vertebrates, in aquatic and terrestrial animals, and among both predators and prey. The major groups of venomous animals are described below.

The pathophysiology of polyneuropathy depends on the type. Chronic inflammatory demyelinating polyneuropathy, for instance, is an autoimmune disease: T cells involvement has been demonstrated, antibodies alone are not capable of demyelination.

Sources: en.wikipedia.org

Notes from published material

=== Prevention and patient education === Early recognition and knowledge of the onset of UCTD can help patients manage and control their disease. Patients should be informed of common agents and triggers to help manage symptoms, to shorten the duration of the disease, and prevent complications.

=== Preventing diabetes mellitus type 1 === Currently, there is no known way to prevent diabetes mellitus type 1. However, onset of diabetes mellitus type 1 may be delayed by about two years by administering Teplizumab.

== Research and partnerships == Mondobiotech investigated whether information already published about naturally occurring human substances could suggest new uses in rare diseases. A 2010 case study by researchers at the University of St. Gallen described its use of scientific literature, external researchers and laboratories, and licensing partners instead of maintaining a conventional in-house laboratory operation. Financial news reporting also described the company's approach as searching medical databases for drug candidates and licensing rights to other companies. In 2002, Mondobiotech and InterMune agreed to collaborate on interferon gamma-1b research for pulmonary diseases, including asthma; the arrangement also covered specified patent rights relating to idiopathic pulmonary fibrosis. In 2006, Biogen Idec licensed rights to develop aviptadil for pulmonary arterial hypertension. The agreement included a US$7.5 million upfront payment and up to US$30 million in possible development and commercialization milestones; the milestone amount was conditional, not a payment already received. Biogen stated in a later regulatory filing that it ended its participation in the aviptadil development program in December 2009. In February 2010, Mondobiotech entered a partnership with Lung Rx, a subsidiary of United Therapeutics, for further development of aviptadil. The company also agreed in 2009 to have Bachem develop and manufacture peptides for its research programs.

Protection: an anatomical barrier from pathogens and damage between the internal and external environment in bodily defence; Langerhans cells in the skin are part of the adaptive immune system. Perspiration contains lysozyme that break the bonds within the cell walls of bacteria. Sensation: contains a variety of nerve endings that react to heat and cold, touch, pressure, vibration, and tissue injury; see somatosensory system and haptics. Heat regulation: the skin contains a blood supply far greater than its requirements, which allows precise control of energy loss by radiation, convection and conduction. Dilated blood vessels increase perfusion and heat loss, while constricted vessels greatly reduce cutaneous blood flow and conserve heat. Control of evaporation: the skin provides a relatively dry and semi-impermeable barrier to fluid loss. Loss of this function contributes to the massive fluid loss in burns. Aesthetics and communication: others see skin and can assess mood, physical state and attractiveness. Storage and synthesis: acts as a storage centre for lipids and water, as well as a means of synthesis of vitamin D by action of UV on certain parts of the skin. Excretion: sweat contains urea, however its concentration is 1/130th that of urine, hence excretion by sweating is at most a secondary function to temperature regulation. Absorption: the cells comprising the outermost 0.25–0.40 mm of the skin are "almost exclusively supplied by external oxygen", although the "contribution to total respiration is negligible".

=== Physiology === Rhabdomyolysis causes the myosin and actin to degenerate into smaller proteins that travel into the circulatory system. The body reacts by increasing intracellular swelling to the injured tissue to send repair cells to the area. This allows creatine kinase and myoglobin to be flushed from the tissue where it travels in the blood until reaching the kidneys. In addition to the proteins released, large quantities of ions such as intracellular potassium, sodium, and chloride find their way into the circulatory system. Intracellular potassium ion has deleterious effects on the heart's ability to generate action potentials leading to cardiac arrhythmias. Consequently, this can affect peripheral and central perfusion which in turn can affect all major organ systems in the body. When the protein reaches the kidneys it causes a strain on the anatomical structures reducing its effectiveness as a filter for the body. The protein acts as a dam as it forms into tight aggregates when it enters the renal tubules. In addition, the increased intracellular calcium has greater time to bind due to the blockage allowing for renal calculi to form. As a result this causes urine output to decrease allowing for the uric acid to build up inside the organ. The increased acid concentration allows the iron from the aggregate protein to be released into the surrounding renal tissue. Iron then strips away molecular bonds of the surrounding tissue which eventually will lead to kidney failure if the tissue damage is too great.

Sources: en.wikipedia.org

Frequently asked questions

What is the main molecular target of cardarine?

It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.

Why did development of GW501516 stop?

Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.

Does cardarine improve endurance in people?

Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.

What is cardarine?

Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.

Network